CI

At a glance

ClinicalIndex Comparison Record
Phase 3Completed· 40 enrolled
Drug / intervention
DAPA Txdrug
Likely dose
DAPA Tx 10mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT04400760
NCT04400760Phase 3Completed
CompareCT.gov

The Effect of Dapagliflozin on Platelet Function testinG Profiles in Diabetic PatiEnts: The EDGE Study.

The University of The West Indies·interventional·Posted May 26, 2020·Updated Nov 7, 2023

In Brief

A Phase 3 clinical trial evaluating DAPA Tx for Platelet Dysfunction. Completed, enrolled 40 participants across 1 site.

Detailed Summary

Sodium GLucose Transport 2 inhibitors (SGLT2I), including dapagliflozin, reduce the likelihood of hospitalization for heart failure and death in persons with type 2 diabetes, of which the mechanism has not been fully elucidated. The mechanistic effects of dapagliflozin on platelet function profiles have not yet been ascertained. It remains unclear if this reduction in cardiovascular death is mediated by decreased platelet reactivity.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsPlatelet Dysfunction
CountriesTrinidad and Tobago
Collaborators--

Timeline

Phase 3CompletedFinished
202120222023202420252026
First PostedMay 26, 2020
Enrollment StartMay 1, 2020
Primary CompletionJun 30, 2022
TodayJul 2, 2026
Enrollment to primary: 2.2 yearsPosted 6.1 years ago

Interventions

DAPA Txdrug

The intervention, dapagliflozin will be administered 10mg per oral daily for two weeks.